ILMN
ILLUMINA, INC.
NASDAQ · Healthcare · Medical - Diagnostics & Research · US
$235.99
−18.64%Price chart
Oct 1Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30
Key dataOct 30, 2026
Open$250.02
From 52W high−19.65%
Volume5.38M
Market cap$35.63B
P/E (TTM)40.1x
P/S (TTM)7.9x
Div yield—
Key dataOct 30, 2026
Open
$250.02
From 52W high
−19.65%
Volume
5.38M
Market cap
$35.63B
ValuationView details →
P/E (Fwd)
39.9x
EV/EBITDA
26.9x
P/E (TTM)
40.1x
RSI (14)
39.1
MomentumView details →
1D Return
−18.64%
YTD Return
+81.38%
SummaryUpdated Sep 1, 2026
Illumina, Inc. (NASDAQ:ILMN) is a leading biotechnology company founded in 1998 and based in San Diego, California, that went public in 2000. The company pioneered the development of DNA sequencing and array-based solutions that have revolutionized genetic and genomic analysis. Over its 25+ year history, Illumina has established itself as the dominant player in the DNA sequencing market, providing the foundational technology that enables genomic research, clinical diagnostics, and personalized medicine applications worldwide.
Similar companies
Latest newsMore news →
ILLUMINA, INC. reported quarterly earnings of $1.44 per share, compared with $1.34 per share a year earlier.1d agoIllumina reported third-quarter fiscal 2026 revenue of $1.13 billion, up 4.2% from the third quarter of 2025.1d agoILLUMINA, INC. added software features to its ILLUMINA, INC. BioInsight platform to accelerate the process from sequencing to discovery.9d ago